Condition: Primary Biliary Cirrhosis · Liver Inflammation · Ursodeoxycholic Acid · Sponsor: University of Aarhus
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.
This description comes directly from the study's public registry record.
Lars Bossen, PhD-student · +4522800676 · larsbossen@clin.au.dk
Always discuss trial participation with your own doctor first.
| Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark | Aarhus C, Central Jutland, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02931513